source
- Merck and Moderna’s melanoma vaccine shows positive Phase 3 results, boosting investor confidenceMerck and Moderna announced that their personalized melanoma vaccine met the primary endpoint of recurrence‑free survival in a Phase 3 trial when given together with Keytruda. The study showed pati…
- Eli Lilly partners with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseasesEli Lilly announced a collaboration with Boston-based Amplitude Therapeutics, a company that emerged from Lilly’s Gateway Labs incubator. The partnership will focus on developing trans-amplifying…Fierce Biotech · 11h agoDealPositive